Neoadjuvant giredestrant plus palbociclib (P) vs. anastrozole (A) plus P in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+, HER2-eBC): Patient (pt)-reported outcomes (PROs) in the randomized, open-label, international phase II coopERA BC study

被引：0
|
作者：
Park, Yeon Hee
Quiroga, Vanesa
Fasching, Peter A.
Bardia, Aditya
Lopez-Valverde, Vanesa
Crnjevic, Tanja Badovinac
Steinseifer, Jutta
Devine, Jacob
Hurvitz, Sara A.
机构：
[1] Samsung Med Ctr, Seoul, South Korea
[2] GEICAM Spanish Breast Canc Grp, Madrid, Spain
[3] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Comprehens Canc Ctr CCC Erlangen EMN, Erlangen, Germany
[4] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA
[5] F Hoffmann La Roche Ltd, Basel, Switzerland
[6] Genentech Inc, South San Francisco, CA USA
[7] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
591
引用
收藏
页数：1
相关论文
共 50 条
  • [31] PHASE II RANDOMIZED STUDY OF PRE-OPERATIVE PF-04691502 PLUS LETROZOLE COMPARED WITH LETROZOLE (L) IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER (BC)
    Dowsett, M.
    Koehler, M.
    Millham, R.
    Borzillo, G.
    A'Hern, R.
    Pierce, K.
    Barton, J.
    Giorgetti, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 44 - 44
  • [32] Interim analyses (IA) of the giredestrant (G), G plus abemaciclib (A), and G plus ribociclib (R) arms in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced/metastatic BC (ER+, HER2-LA/mBC).
    Oliveira, Mafalda
    Sonnenblick, Amir
    Rugo, Hope S.
    Jung, Kyung Hae
    Yam, Einav Gal
    Hurvitz, Sara A.
    Hernando, Cristina
    Im, Seock-Ah
    Breton, Vanessa
    Collier, Ann
    Schwab, Richard B.
    Zhu, Jing
    Sohn, Joohyuk
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] Elacestrant in combination with abemaciclib in patients (pts) with brain metastasis (mets) from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer: Preliminary data from ELECTRA, an open-label, multicenter, phase Ib/II study
    Ciruelos, E. M.
    Hamilton, E. P.
    Kim, S-B.
    Im, Y-H.
    Solis, E. Segui
    Saenz, J. A. Garcia
    Di Sanzo, A.
    Lizarbe, M. Dominguez
    Wasserman, T.
    Theall, K. P.
    Ibrahim, N. K.
    ANNALS OF ONCOLOGY, 2024, 35 : S370 - S370
  • [34] Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial
    Tibau, Ariadna
    Martinez, M. Teresa
    Ramos, Manuel
    de la Cruz-Merino, Luis
    Santaballa, Ana
    O'Connor, Miriam
    Martinez-Janez, Noelia
    Moreno, Fernando
    Fernandez, Isaura
    Virizuela, Juan Antonio
    Alarcon, Jesus
    de la Haba-Rodriguez, Juan
    Sanchez-Rovira, Pedro
    Albacar, Cinta Rosa
    Muino, Coralia Bueno
    Kelly, Catherine
    Casas, Maribel
    Bezares, Susana
    Rosell, Libertad
    Albanell, Joan
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [35] Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 study
    Ahn, Hee Kyung
    Kim, Ji-Yeon
    Lee, Kyung-Hun
    Kim, Gun Min
    Kang, Seok Yun
    Lee, Keun Seok
    Kim, Jee Hyun
    Lee, Kyong Eun
    Lee, Moon Hee
    Kim, Hee-Jun
    Kim, Han Jo
    Koh, Su-Jin
    Park, In Hae
    Sohn, Joohyuk
    Kim, Sung-Bae
    Ahn, Jin Seok
    Kim, Seonwoo
    Cho, Hyun
    Jung, Kyung Hae
    Im, Seock-Ah
    Park, Yeon Hee
    LANCET ONCOLOGY, 2025, 26 (03): : 343 - 354
  • [36] A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-9545, in postmenopausal women with estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer
    Jhaveri, Komal
    Winer, Eric Paul
    Lim, Elgene
    Fidalgo, Jose AlejandroPerez
    Bellet, Meritxell
    Mayer, Ingrid Alina
    Boni, Valentina
    Patel, Jaymin M.
    Bardia, Aditya
    Garcia, Jose Manuel
    Kabos, Peter
    Gates, Mary
    Chen, Ya-Chi
    Fredrickson, Jill
    Wang, Xiaojing
    Friedman, Lori Sickels
    Spoerke, Jill
    Gendreau, Steven
    Metcalfe, Ciara
    Liu, Lichuan
    Chang, Ching-Wei
    Monemi, Sharareh
    Gonzalez, Monica
    McCurry, Ursula
    Milan, Sandra
    Humke, Eric William
    Loi, Sherene
    CANCER RESEARCH, 2020, 80 (04)
  • [37] Interim analysis (IA) of the giredestrant (G) plus everolimus (EVERO) arm in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)
    Wander, Seth Andrew
    Stemmer, Salomon M.
    Rugo, Hope S.
    Im, Seock-Ah
    Lau, Peter Kar Han
    Paluch-Shimon, Shani
    Cahuzac, Clelia
    Collier, Annie
    Shah, Mona D.
    Ngo, Huy X.
    Schwab, Richard B.
    Zhu, Jing
    Oliveira, Mafalda
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] ELEVATE: A phase 1b/2, open-label, umbrella study evaluating elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC)
    Rugo, Hope
    Bardia, Aditya
    Cortes, Javier
    Curigliano, Giuseppe
    Hamilton, Erika
    Hurvitz, Sara
    Loibl, Sibylle
    Tolaney, Sara
    Kaklamani, Virginia
    Tonini, Giulia
    Matheny, Shannon
    Theall, Kathy Puvana
    O'Shaughnessy, Joyce
    CANCER RESEARCH, 2024, 84 (09)
  • [39] TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer
    Christos Vaklavas
    Brian S. Roberts
    Katherine E. Varley
    Nancy U. Lin
    Minetta C. Liu
    Hope S. Rugo
    Shannon Puhalla
    Rita Nanda
    Anna Maria Storniolo
    Lisa A. Carey
    Mansoor N. Saleh
    Yufeng Li
    Jennifer F. Delossantos
    William E. Grizzle
    Albert F. LoBuglio
    Richard M. Myers
    Andres Forero-Torres
    Breast Cancer Research, 22
  • [40] TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer
    Vaklavas, Christos
    Roberts, Brian S.
    Varley, Katherine E.
    Lin, Nancy U.
    Liu, Minetta C.
    Rugo, Hope S.
    Puhalla, Shannon
    Nanda, Rita
    Storniolo, Anna Maria
    Carey, Lisa A.
    Saleh, Mansoor N.
    Li, Yufeng
    Delossantos, Jennifer F.
    Grizzle, William E.
    LoBuglio, Albert F.
    Myers, Richard M.
    Forero-Torres, Andres
    BREAST CANCER RESEARCH, 2020, 22 (01)
12345